xMedica

NCT07206056ClinicalTrials.gov

An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

TulmiSTAR-01: A Two-part, Phase I Dose Escalation and Expansion Followed by a Randomized, Open-label Multicenter, Phase II Study to Assess the Safety and Efficacy of the Combination of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) vs Standard of Care in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer

قيد التجنيديقبل مشاركين الآن، وفقاً لسجل السجل.
التواصل مع هذه الدراسة

باختصار

This is a two-part, Phase I/II, open-label, global, multicenter study assessing the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) versus standard of care in participants with progressive metastatic castrate resistant prostate cancer (mCRPC).

المرحلة 1 / المرحلة 2مطلوب 188 مشاركاً35 موقعاً14 دولة

الفئات

علم الأورام68%الكلى والمسالك البولية32%

مسجَّلة في سجل واحد

يمكن أن تُسجَّل دراسة واحدة في عدة سجلات. نعرضها مرة واحدة ونربط بكل سجل نحتفظ به.

تُعرض معلومات التجربة كما نشرها السجل، بلغتها الأصلية.

هل أنت مهتم بهذه الدراسة؟

تسجيل الدخول أو أنشئ حسابًا لتسجيل اهتمامك ومتابعة هذه الدراسة.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Registered before enrolment beganFirst posted 2025-10-03; recorded start 2025-10-15
  • Has a defined primary outcomeA primary outcome measure is listed in the record
  • The primary outcome states a time frameThe primary outcome measure records a time frame
  • Participants are randomly assignedAllocation is recorded as randomised
  • Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Open label (no blinding)Masking is recorded as none (open label)
  • An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Sponsor has 1128 other studies in this databaseCounted from the lead sponsor named in the record (Novartis Pharmaceuticals)
  • Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

These are facts from the public registry record, not a judgement about the study. Discuss any trial with your own doctor before taking part.

What these facts mean, and what to ask · ruleset v1

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 2 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding0/20

    Open-label

  • Control arm15/15

    Active-comparator control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 33 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study, international in scope: 188 participants (target), run at 35 sites, across 14 countries.

How this score is built
  • Enrolment22/40

    188 participants (target)

  • Site count18/25

    33 sites

  • Country count12/15

    14 countries

  • Planned duration10/10

    Planned over about 62 months

  • Sponsor scale10/10

    Novartis Pharmaceuticals has led 1,104 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

ملخص

This is a two-part, Phase I/II, open-label, global, multicenter study assessing the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) versus standard of care in participants with progressive metastatic castrate resistant prostate cancer (mCRPC).

The Phase 1 study, comprised of Parts 1a and 1b, aims to assess the safety and tolerability of the combination of tulmimetostat and JSB462: 1. Part 1a is the parallel dose escalation that aims to determine the recommended dose(s) of tulmimetostat and JSB462, in combination, for further exploration. 2. Part 1b is the dose expansion/optimization that aims to determine the recommended dose of the combination for Phase II. The purpose of the Phase II study (Part 2) is to compare the combination of tulmimetostat with JSB462 in terms of the biochemical response as assessed by PSA50 compared to the standard of care (SoC) in adult men with progressive, taxane-naive mCRPC.

الحالات

  • Progressive Metastatic Castrate Resistant Prostate Cancer

الأهلية

الجنسذكر
الأعمار18 Years – لا حد أقصى
المتطوعون الأصحّاءلا

الأهلية كما كُتبت في السجل

Key Inclusion Criteria: * Participant is an adult man ≥ 18 years of age. * Participant must have histologically and/or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine or small cell features (current or prior biopsy of the prostate and/or metastatic site). * Participant must have ≥ 1 metastatic lesion that is present on screening/baseline CT, MRI, or bone scan imaging obtained ≤ 28 days prior to start of treatment (Part 1a dose escalation) or randomization (Part 1b dose expansion and Part 2). * Participant must have progressive mCRPC. * Participant must have a castrate level of serum/plasma testosterone (\< 50 ng/dL or \< 1.7 nmol/L). * Prior ARPI therapy: * Part 1a and 1b only: must have progressed on at least one prior second generation ARPI (abiraterone, enzalutamide, darolutamide, or apalutamide). * Part 2 only: must have progressed on one prior second generation ARPI (abiraterone, enzalutamide, darolutamide, or apalutamide). * Prior chemotherapy: * Part 1a dose escalation only: may have received ≤ 2 prior lines of chemotherapy in CRPC setting. Note: Prior chemotherapy is permitted in the HSPC setting. * Part 1b dose expansion/optimization only: may have received up to one prior line of chemotherapy in CRPC setting. Note: Prior chemotherapy is permitted in the HSPC setting. * Part 2 only: Participants must be taxane-naïve in mCRPC setting; prior chemotherapy permitted in HSPC setting only Key Exclusion Criteria: * Previous treatment with any PRC2 inhibitor, including but not limited to EZH2 inhibitors, EZH2/1 inhibitors, or embryonic ectoderm development (EED) inhibitors. * Previous treatment with a protein degrader compound that targets the AR. * Known hypersensitivity or contraindication to any of the study treatment components or its excipients or to drugs of similar chemical classes. * Treatment with any investigational agent within 28 days (or 5 half-lives, whichever is longer) prior to study entry. * Previous treatment with radioligand therapy in the mCRPC setting, except in Part 1a where participants may have received RLT in mCRPC setting. * Participants with evidence of mCRPC or biochemical recurrence / PSA only disease or asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy and with normal PSA for ≥ 1 year prior to study entry. * Participants with a history of CNS metastases must have received therapy (surgery, radiotherapy, gamma knife) and be neurologically stable, asymptomatic, and not receiving corticosteroids for the purpose of maintaining neurologic integrity. Those with leptomeningeal disease are eligible if those areas have been treated, are stable, and no neurological impairment is present. For those with parenchymal CNS metastasis (or a history of CNS metastasis), baseline and subsequent radiological imaging must include evaluation of the brain with MRI (preferred) or CT with contrast. Other protocol-defined inclusion/exclusion criteria may apply.

الأهلية في عبارات بسيطة

لم تُقسَّم معايير هذا السجل إلى عبارات منفصلة بعد. نص السجل أعلاه كامل وهو النسخة المُعتمَدة.

تصميم الدراسة

نوع الدراسةتدخّلية
المرحلةالمرحلة 1 / المرحلة 2
التخصيصمعشّاة
نموذج التدخّلPARALLEL
الغرض الأساسيTREATMENT
التعميةNONE (0)
التجنيدمطلوب 188 مشاركاً

الجهة الراعية والمتعاونون

  • Novartis Pharmaceuticals الجهة الراعية

الأذرع والتدخلات

  • Part 2: Arm 2ACTIVE_COMPARATOR

    Standard of Care at the discretion of the investigator

  • Part 1b : Arm AEXPERIMENTAL

    Tulmimetostat Dose 1 QD + JSB462 QD

  • Part 1b: Arm BEXPERIMENTAL

    Tulmimetostat Dose 2 QD + JSB462 QD

  • Part 1a: Cohort DL1AEXPERIMENTAL

    Tulmimetostat DL1 QD + JSB462 Dose 1 QD

  • Part 1a: Cohort DL1BEXPERIMENTAL

    Tulmimetostat DL1 QD + JSB462 Dose 2 QD

  • Part 1a: Cohort DL2AEXPERIMENTAL

    Tulmimetostat DL2 QD + JSB462 Dose 1 QD

  • Part 1a: Cohort DL2BEXPERIMENTAL

    Tulmimetostat DL2 QD + JSB462 Dose 2 QD

  • Part 1a: Cohort DL3AEXPERIMENTAL

    Tulmimetostat DL3 QD + JSB462 Dose 1 QD

  • Part 1a: Cohort DL3BEXPERIMENTAL

    Tulmimetostat DL3 QD + JSB462 Dose 2 QD

  • Part 2: Arm 1EXPERIMENTAL

    Tulmimetostat RP2D QD + JSB462 QD

التدخلات

  • دواء JSB462 Dose 1 QD

    JSB462 Dose 1 QD

  • دواء JSB462 Dose 2 QD

    JSB462 Dose 2 QD

  • دواء JSB462 QD

    The dose of JSB462 QD will be determined based on the totality of data from Part 1a

  • دواء Standard of Care (SoC)

    Androgen Receptor Pathway Inhibitors (ARPI), chemotherapy or Pluvicto (AAA617) at the discretion of the investigator

  • دواء Tulmimetostat DL1 QD

    Part 1a (dose escalation): Doses of tulmimetostat beyond DL1 once a day (QD) will be opened depending on outcome of Dose Escalation Meetings (DEM(s))

  • دواء Tulmimetostat DL2 QD

    Part 1a (dose escalation): Doses of tulmimetostat beyond DL1 once a day (QD) will be opened depending on outcome of Dose Escalation Meetings (DEM(s))

  • دواء Tulmimetostat DL3 QD

    Part 1a (dose escalation): Doses of tulmimetostat beyond DL1 once a day (QD) will be opened depending on outcome of Dose Escalation Meetings (DEM(s))

  • دواء Tulmimetostat Doses 1 or 2 QD

    Part 1b (dose expansion and optimization): tulmimetostat doses 1 or 2 QD

  • دواء Tulmimetostat RP2D QD

    Part 2: tulmimetostat Recommended Phase 2 Dose (RP2D) QD

مقاييس النتائج

  1. مقياس النتيجة الأولي

    Part 1a: Dose-limiting toxicities (DLTs)

    A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness/injury, or concomitant medications that occurs within the first 28 days of treatment with tulmimetostat and JSB462 and meets any of the criteria specified in the protocol. The National Cancer Institute Common Terminology Criteria for Adverse events (NCI CTCAE) version 5.0 will be used for all grading. For the purpose of dose-escalation decisions, DLTs will be considered and included in the Bayesian Logistic Regression Model (BLRM).

    الإطار الزمني Up to 28 days

  2. مقياس النتيجة الأولي

    Part 1a and Part 1b: Incidence rate of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    The analysis of adverse events will include categorization by type, frequency, and severity, as graded by the NCI CTCAE version 5.0.

    الإطار الزمني From date of randomization till 30 days safety fup, assessed up to approximately 14 months

  3. مقياس النتيجة الأولي

    Part 1a and Part 1b: Number of Participants with dose adjustments

    The number of participants with dose adjustments (reductions, interruption, or permanent discontinuation) will be summarized by treatment arm.

    الإطار الزمني From date of randomization till 30 days safety fup, assessed up to approximately 14 months

  4. مقياس النتيجة الأولي

    Part 1a and Part 1b: Dose Intensity

    Dose intensity (computed as the ratio of actual cumulative dose received and actual duration of exposure) and the relative dose intensity (computed as the ratio of dose intensity and planned dose intensity) will be summarized by means of descriptive statistics

    الإطار الزمني From date of randomization till 30 days safety fup, assessed up to approximately 14 months

  5. مقياس النتيجة الأولي

    Part 1a and Part 1b: Duration of exposure to each study drug

    The duration of exposure (in months) to Tulmimetostat and JSB462 (Part 1a and Part 1b) will be summarized by means of descriptive statistics

    الإطار الزمني From date of randomization till 30 days safety fup, assessed up to approximately 14 months

  6. مقياس النتيجة الأولي

    Part 1b and Part 2: prostate-specific antigen 50 (PSA50) at Month 6

    PSA50 is defined as a PSA reduction of at least 50% from baseline at 6 months confirmed by a second PSA measurement ≥ 3 weeks later.

    الإطار الزمني Month 6

  7. مقياس النتيجة الثانوي

    Part 1a and Part 1b: Plasma concentrations of tulmimetostat and JSB462

    Tulmimetostat and JSB462 pharmacokinetic (PK) samples will be obtained and evaluated in all participants at all dose levels by treatment arms

    الإطار الزمني Cycle 1-2: Day 1 (predose/0 hour, 1 hour, 2 hours, 4 hours, 6 hours and 8 hours; Tulmimetostat only: 30 minutes and 3 hours). Cycle 1: Day 2 (24 hours), Days 8 and 15 (predose/0 hour and 2 hours). Cycles 3-5: Day 1 (predose/0 hour). 1 cycle = 28 days.

  8. مقياس النتيجة الثانوي

    Part 2: Plasma concentrations of tulmimetostat and JSB462

    Tulmimetostat and JSB462 pharmacokinetic (PK) samples will be obtained and evaluated in all participants at all dose levels by treatment arms

    الإطار الزمني Cycle 1 and 2: Day 1 (predose/0 hour and 2 hours). Cycles 3-5: Day 1 (predose/0 hour). 1 cycle = 28 days.

  9. مقياس النتيجة الثانوي

    Part 1a and Part 1b: AUC of tulmimetostat and JSB462

    Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. Area under the concentration-time curve from time zero to the time of last quantifiable concentration (AUClast) and Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUCinf) will be listed and summarized using descriptive statistics.

    الإطار الزمني Cycle 1-2: Day 1 (predose/0 hour, 1 hour, 2 hours, 4 hours, 6 hours and 8 hours; Tulmimetostat only: 30 minutes and 3 hours). Cycle 1: Day 2 (24 hours), Days 8 and 15 (predose/0 hour and 2 hours). Cycles 3-5: Day 1 (predose/0 hour). 1 cycle = 28 days.

  10. مقياس النتيجة الثانوي

    Part 2: AUC of tulmimetostat and JSB462

    Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. Area under the concentration-time curve from time zero to the time of last quantifiable concentration (AUClast) and Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUCinf) will be listed and summarized using descriptive statistics.

    الإطار الزمني Cycle 1 and 2: Day 1 (predose/0 hour and 2 hours). Cycles 3-5: Day 1 (predose/0 hour). 1 cycle = 28 days.

  11. مقياس النتيجة الثانوي

    Part 1a and Part 1b: Cmax of tulmimetostat and JSB462

    Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. Cmax will be listed and summarized using descriptive statistics.

    الإطار الزمني Cycle 1-2: Day 1 (predose/0 hour, 1 hour, 2 hours, 4 hours, 6 hours and 8 hours; Tulmimetostat only: 30 minutes and 3 hours). Cycle 1: Day 2 (24 hours), Days 8 and 15 (predose/0 hour and 2 hours). Cycles 3-5: Day 1 (predose/0 hour). 1 cycle = 28 days.

  12. مقياس النتيجة الثانوي

    Part 2: Cmax of tulmimetostat and JSB462

    Venous whole blood samples will be collected for activity-based pharmacokinetics characterization. Cmax will be listed and summarized using descriptive statistics.

    الإطار الزمني Cycle 1 and 2: Day 1 (predose/0 hour and 2 hours). Cycles 3-5: Day 1 (predose/0 hour). 1 cycle = 28 days.

  13. مقياس النتيجة الثانوي

    Part 1b and Part 2: prostate-specific antigen 50 (PSA50) at 3, 9, and 12 months

    PSA50 is defined as a PSA reduction of at least 50% from baseline at 3, 9, and 12 months confirmed by a second PSA measurement ≥ 3 weeks later.

    الإطار الزمني Month 3, Month 9, Month 12

  14. مقياس النتيجة الثانوي

    Part 1b and Part 2: radiographic progression free survival (rPFS)

    rPFS is defined as time between randomization and the first occurrence of disease progression as per PCWG3-modified RECIST v1.1 or death due to any cause

    الإطار الزمني From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to approximately 15 months

  15. مقياس النتيجة الثانوي

    Part 1b and Part 2: overall survival (OS)

    OS is defined as the time between randomization to date of death due to any cause

    الإطار الزمني From date of randomization until date of death from any cause, assessed up to approximately 15 months

  16. مقياس النتيجة الثانوي

    Part 1b and Part 2: objective response (OR)

    OR is defined as a confirmed complete response (CR) or partial response (PR) per PCWG3-modified RECIST 1.1 as assessed by the investigator

    الإطار الزمني From date of randomization until date of progression or date of death from any cause, whichever come first, assessed up to approximately 15 months

  17. مقياس النتيجة الثانوي

    Part 1b and Part 2: best overall response (BOR)

    BOR is defined as the best response per Prostate Cancer Working Group 3 (PCWG3)-modified RECIST 1.1 as assessed by the Investigator

    الإطار الزمني From date of randomization until date of progression or date of death from any cause, whichever come first, assessed up to approximately 15 months

  18. مقياس النتيجة الثانوي

    Part 1b and Part 2: duration of response (DOR)

    DOR is defined as time between first documented CR/PR and disease progression or death due to any cause per PCWG3-modified RECIST 1.1 as assessed by the investigator

    الإطار الزمني From date of randomization until date of progression or date of death from any cause, whichever come first, assessed up to approximately 15 months

  19. مقياس النتيجة الثانوي

    Part 1b and Part 2: time to first symptomatic skeletal event (TTSSE)

    TTSSE is defined as time from randomization to the first new symptomatic pathological bone fracture, spinal cord compression, tumor-related orthopedic surgical intervention, requirement for radiation therapy to relieve bone pain or death from any cause, whichever occurs first.

    الإطار الزمني From randomization until the first occurrence of a new symptomatic bone fracture, spinal cord compression, tumor-related orthopedic surgery, radiation therapy for bone pain, or death, assessed up to 15 months.

  20. مقياس النتيجة الثانوي

    Part 2: Incidence rate of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    The analysis of adverse events will include categorization by type, frequency, and severity, as graded by the NCI CTCAE version 5.0.

    الإطار الزمني From date of randomization till 30 days safety fup, assessed up to approximately 15 months

  21. مقياس النتيجة الثانوي

    Part 2: Number of Participants with dose adjustments

    The number of participants with dose adjustments (reductions, interruption, or permanent discontinuation) will be summarized by treatment arm.

    الإطار الزمني From date of randomization till 30 days safety fup, assessed up to approximately 15 months

  22. مقياس النتيجة الثانوي

    Part 2: Dose Intensity

    Dose intensity (computed as the ratio of actual cumulative dose received and actual duration of exposure) and the relative dose intensity (computed as the ratio of dose intensity and planned dose intensity) will be summarized by means of descriptive statistics

    الإطار الزمني From date of randomization till 30 days safety fup, assessed up to approximately 15 months

  23. مقياس النتيجة الثانوي

    Part 2: Duration of exposure to each study drug

    The duration of exposure (in months) to Tulmimetostat and JSB462 / Standard of Care (SoC) of investigator's choice (Part 2) will be summarized within each strata by means of descriptive statistics

    الإطار الزمني From date of randomization till 30 days safety fup, assessed up to approximately 15 months

التواريخ

تاريخ البدء15 أكتوبر 2025 (فعلي)
الإتمام الأولي9 نوفمبر 2029 (تقديري)
الإتمام1 ديسمبر 2030 (تقديري)
أول نشر3 أكتوبر 2025 (فعلي)
آخر تحديث18 سبتمبر 2026
النتائج منشورةغير مذكور في سجل السجل
آخر تأكيد للحالةسبتمبر 2026

فعلي يعني أن الحدث وقع. تقديري يعني أن الجهة الراعية تتوقعه. للكلمتين معنيان مختلفان.

المواقع

35 موقعاً قيد التجنيد

Australia

المنشأةالمدينةالولاية أو المنطقةالحالة
Novartis Investigative SiteLiverpoolقيد التجنيد
Novartis Investigative SiteMelbourneVictoriaقيد التجنيد
Novartis Investigative SiteSt LeonardsNew South Walesقيد التجنيد

Canada

المنشأةالمدينةالولاية أو المنطقةالحالة
Novartis Investigative SiteHalifaxNova Scotiaقيد التجنيد

China

المنشأةالمدينةالولاية أو المنطقةالحالة
Novartis Investigative SiteBeijingقيد التجنيد

Denmark

المنشأةالمدينةالولاية أو المنطقةالحالة
Novartis Investigative SiteHerlevقيد التجنيد
Novartis Investigative SiteOdense Cقيد التجنيد
Novartis Investigative SiteVejleقيد التجنيد

France

المنشأةالمدينةالولاية أو المنطقةالحالة
Novartis Investigative SiteBordeauxقيد التجنيد
Novartis Investigative SiteParisقيد التجنيد
Novartis Investigative SiteParisقيد التجنيد

Germany

المنشأةالمدينةالولاية أو المنطقةالحالة
Novartis Investigative SiteDüsseldorfNorth Rhine-Westphaliaقيد التجنيد
Novartis Investigative SiteJenaThuringiaقيد التجنيد

Italy

المنشأةالمدينةالولاية أو المنطقةالحالة
Novartis Investigative SiteMilanMIقيد التجنيد
Novartis Investigative SiteOrbassanoTOقيد التجنيد
Novartis Investigative SitePadovaPDقيد التجنيد

Malaysia

المنشأةالمدينةالولاية أو المنطقةالحالة
Novartis Investigative SiteKuchingSarawakقيد التجنيد

Mexico

المنشأةالمدينةالولاية أو المنطقةالحالة
Novartis Investigative SiteTlalpanMexico Cityقيد التجنيد

Poland

المنشأةالمدينةالولاية أو المنطقةالحالة
Novartis Investigative SitePoznanقيد التجنيد

Singapore

المنشأةالمدينةالولاية أو المنطقةالحالة
Novartis Investigative SiteSingaporeقيد التجنيد
Novartis Investigative SiteSingaporeقيد التجنيد

Spain

المنشأةالمدينةالولاية أو المنطقةالحالة
Novartis Investigative SiteL'Hospitalet de LlobregatBarcelonaقيد التجنيد
Novartis Investigative SiteMadridقيد التجنيد
Novartis Investigative SiteMadridقيد التجنيد
Novartis Investigative SiteSantiago CompostelaA Corunaقيد التجنيد

United Kingdom

المنشأةالمدينةالولاية أو المنطقةالحالة
Novartis Investigative SiteLondonقيد التجنيد
Novartis Investigative SiteSuttonSurreyقيد التجنيد

United States

المنشأةالمدينةالولاية أو المنطقةالحالة
Emory UniversityAtlantaGeorgiaقيد التجنيد
Mass General HospitalBostonMassachusettsقيد التجنيد
Cleveland Clinic FoundationClevelandOhioقيد التجنيد
Sarah Cannon Research InstituteDenverColoradoقيد التجنيد
Duke University Medical CenterDurhamNorth Carolinaقيد التجنيد
Sarah Cannon Research InstituteJacksonvilleFloridaقيد التجنيد
Fred Hutchinson Cancer Research CenterSeattleWashingtonقيد التجنيد
Wichita Urology Group PAWichitaKansasقيد التجنيد

مستندات الدراسة

لا تُرتبط أي مستندات في سجل السجل هذا.

التغيّرات عبر الزمن

  1. 21 أغسطس 2026

    أُضيف موقع

    1 site added (35 total)

    3435

  2. 18 أغسطس 2026

    أُضيف موقع

    1 site added (34 total)

    3334

السجل: ClinicalTrials.gov · NCT########

https://xmedica.io/trials/ctgov/NCT07206056